Entering text into the input field will update the search result below

Competent Cells Market Development And Business Intelligence

Jul. 28, 2020 11:19 AM ET
Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Seeking Alpha Analyst Since 2014

#Healthcare Consultant focusing on #TeleHealth #TeleMedicine #PatientPortals #CVIS #HCIT #MedicalRobots #Vaccines #MedicalDevices #WirelessHealth #Biotechnology


  • Key Growth Factors of the Competent Cells Market.
  • Global Market Size & Leading players.
  • Top growing segments of this industry.

Market growth influenced due to following factors-

  • Advancements in molecular cloning research.
  • Increasing intensity of research and technological advancements in competent cells.
  • Rising investments in research for developing genomics and proteomics-based products.

Global market size-

According to market research report the competent cells market is projected to reach $2.22 billion by 2022, at a CAGR of 10.2%.

Leading players –

Product launches, acquisitions, and partnerships were some of the major strategies followed by key players in the competent cells market. These strategies were adopted by—Thermo Fisher Scientific, Inc. (U.S.), Merck KGaA (Germany), New England Biolabs (U.S.), GenScript Biotech Corporation (CHINA), and Agilent Technologies, Inc. (U.S.).

For Details, Download PDF Brochure Here

Top Segment – • By type, the chemically competent cells segment is expected to dominate the market in 2017• By application, the cloning segment is expected to dominate the market in 2017• By end user, the academic research institutes segment is expected to dominate the market in 2017• North America to dominate the competent cells market in 2017

The market is dominated by North America, followed by Europe. The North American region is expected to grow at the fastest CAGR during the forecast period. This is primarily due to increase in the R&D activities in the region.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.